We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

8 hedge funds and large institutions have $6.52M invested in Galmed Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

45% more capital invested

Capital invested by funds: $4.49M → $6.52M (+$2.02M)

14% more funds holding

Funds holding: 7 → 8 (+1)

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GL
GLG LLC
New York
+$475K
2
Morgan Stanley
Morgan Stanley
New York
+$211K
3
SKK
Shepherd Kaplan Krochuk
Massachusetts
+$97.9K
4
UBS Group
UBS Group
Switzerland
+$37.7K

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$100K
2
Wells Fargo
Wells Fargo
California
-$24K

GLMD Hedge Fund Activity: Q2 2017 in Review

8 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2017, worth a combined $6.52M — up 45% from $4.49M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new GLMD positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was GLG LLC, opening a new position worth an estimated $475K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $100K sold.

  • 8 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2017, up from 7 in Q1 2017.
  • Funds reported $6.52M of Galmed Pharmaceuticals stock for Q2 2017, up 45% quarter-over-quarter.
  • 3 funds opened new Galmed Pharmaceuticals positions in Q2 2017 and 2 closed out, a net change of +1 holder.
  • The largest Galmed Pharmaceuticals buyer in Q2 2017 was GLG LLC, an estimated $475K added.
  • The largest Galmed Pharmaceuticals seller in Q2 2017 was Virtu KCG Holdings, an estimated $100K sold.

Based on aggregated 13F filings for Q2 2017.